Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy.
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
Fort Worth Star-Telegram9d
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...
Moderna Secures European Contract For Covid-19 Vaccine
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
Moderna extends gains as EU offers COVID vaccine contract
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...
Miami Herald9d
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
"Diversity of supply and availability of vaccine formats such as pre-filled ... With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future ...